PMHNP Scope of Practice for ADHD in Illinois

You’re a psychiatrist or psychiatric nurse practitioner looking at the telehealth ADHD space, and the first question that hits you is: Can I legally prescribe Adderall or Ritalin to a patient I’ve never met in person?

The answer right now – through the end of 2026 – is yes, thanks to federal emergency rules that waived the in-person exam requirement for controlled substances. But the situation is more nuanced than a simple ‘yes,’ because federal law is temporary, state rules vary wildly, and your scope of practice (especially if you’re an NP) creates different constraints depending on where your patient lives.

Let’s cut through the regulatory fog. This guide walks you through what you can actually do today, what’s coming in 2027, and how each of our six priority states – California, Texas, Florida, New York, Pennsylvania, and Illinois – handles telehealth ADHD prescribing differently.

The Federal Picture: Temporary Green Light, But Rules Are Coming

The Ryan Haight Act and COVID Waivers

Under normal circumstances, federal law (the Ryan Haight Act) requires an in-person medical exam before you can prescribe any controlled substance – including Schedule II stimulants like Adderall, Ritalin, or Vyvanse. This wasn’t a suggestion; it was a hard stop that effectively killed pure telehealth ADHD practices before 2020.

COVID changed everything. In March 2020, the DEA invoked emergency authority and waived the in-person requirement entirely for telehealth prescribing of Schedule II–V controlled substances. The catch? You still had to conduct a legitimate evaluation via real-time audio-video (not just a questionnaire or phone call), document it properly, and prescribe for a legitimate medical purpose.

That waiver kept getting extended. As of January 2026, DEA and HHS announced the fourth extension, running through December 31, 2026. Translation: for the next year, you can initiate and continue ADHD treatment entirely via video visits without ever seeing the patient in person, as long as you’re following standard controlled substance protocols (DEA registration, state PDMP checks, e-prescribing, etc.).

What Happens in 2027? DEA’s Permanent Rules

The extensions are stopgaps while DEA finalizes permanent telemedicine rules. In January 2025, DEA previewed three new regulations that will reshape telehealth prescribing:

1. Telemedicine Special Registration: DEA is creating a new pathway for providers to prescribe controlled substances via telehealth without an in-person visit – but only if you obtain a special DEA telemedicine registration. This registration will require:

• Mandatory nationwide PDMP checks for every patient
• Strict patient identity verification during video consults
• Registration of telehealth platforms (like Klarity) with the DEA, not just individual providers

2. Established Patient Exception: If you’ve seen a patient in person at least once (or another provider in your practice has), the new telemedicine rules won’t apply to ongoing care. In other words, once there’s a physical visit on record, you can continue via telehealth indefinitely.

3. Modified Initial Supply Rules: While DEA scrapped its original proposal to limit new telehealth patients to a 30-day stimulant supply, the final rules will likely include some tiered approach – possibly allowing a 30-day initial prescription without special registration, but requiring registration or an in-person visit for long-term treatment.

The timeline: Expect these rules to take effect in early-to-mid 2027. Until then, the current extension gives you breathing room. But if you’re building a telehealth ADHD practice, plan to get that special registration when it becomes available – or factor in periodic in-person visits as a backup strategy.

Economic Reality: Why Federal Rules Matter More Than You Think

Here’s what most ‘start your telehealth practice’ content won’t tell you: acquiring psychiatric patients on your own typically costs $200–500+ per booked appointment when you factor in all the real costs:

• Google Ads for mental health keywords run $15–40+ per click, and most clicks don’t convert
• SEO takes 6–12 months of consistent investment before generating meaningful patient flow
• Psychology Today and Zocdoc charge monthly fees and per-booking fees, and you’re competing with hundreds of other providers on the same page
• Agency/consultant fees, ad optimization testing, staff time to qualify leads, no-shows from cold leads – it all adds up fast

Most solo practitioners don’t have $3,000–5,000/month to gamble on marketing with uncertain results. The federal telehealth rules matter because platforms like Klarity can deliver pre-qualified ADHD patients under a pay-per-appointment model – you only pay when a matched patient actually books with you. That’s guaranteed ROI vs. burning cash on ads that might convert.

When federal rules shift in 2027, platforms that handle compliance (PDMP integration, identity verification, DEA registration support) will be worth their weight in gold, because DIY telehealth compliance will become significantly more complex.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Breakdown: Where Regulations Actually Bite

Federal law sets the floor, but states control licensing, scope of practice, and can add their own telehealth restrictions. Here’s what matters in each priority state:

California: Open Road for Telehealth, NP Independence Coming

The Rules:

• No state-imposed in-person exam requirement beyond federal law
• Telehealth evaluation explicitly satisfies prescribing standards – even asynchronous questionnaires can count if clinically appropriate (though best practice is video for ADHD diagnosis)
• No special prohibition on prescribing stimulants via telehealth

NP Scope:California is transitioning to Full Practice Authority for nurse practitioners. Under AB 890 (passed 2020), experienced NPs can practice independently without physician supervision – including prescribing Schedule II stimulants – once they complete 3 years or 4,600 hours under physician oversight. By 2026, any NP meeting these criteria can apply for independent practice status.

For new-grad NPs, you still need a supervising physician initially. But the trajectory is clear: California is actively expanding psychiatric NP autonomy.

Key Requirements:

• CURES PDMP: Mandatory check before prescribing any Schedule II stimulant for the first time, then every 4 months for ongoing treatment
• Licensure: Must hold a California medical license (no telehealth registration option; CA isn’t in the Interstate Medical Licensure Compact)
• E-prescribing: Required for controlled substances

Bottom Line: California makes telehealth ADHD prescribing straightforward. The main barrier is getting licensed in the first place (CA licensing can take 6+ months for out-of-state providers), but once you’re in, there are no special telehealth hoops to jump through. The expanding NP independence is a huge advantage for telehealth platforms looking to scale.

Texas: Physicians Only for Stimulants

The Rules:

• Telehealth permitted for mental health treatment; no state ban on prescribing ADHD meds via video
• Standard of care must be met (proper evaluation, documentation)

The Problem:Texas law prohibits nurse practitioners and physician assistants from prescribing Schedule II controlled substances in outpatient settings. Period.

The only exceptions are hospital inpatients (≥24 hours), hospice patients, or emergency room orders. Outpatient ADHD treatment doesn’t qualify. This means only physicians (MD/DO) can write prescriptions for Adderall, Ritalin, or any other Schedule II stimulant for your telehealth ADHD patients in Texas.

NP Scope:Texas NPs can prescribe Schedule III–V with physician delegation and must consult their supervising physician after 90 days or for pediatric patients. But stimulants? Nope. A physician must handle every prescription.

Key Requirements:

• PDMP: Texas mandates PDMP checks for opioids, benzos, barbiturates, and carisoprodol – stimulants aren’t explicitly required, but checking is best practice
• E-prescribing: Mandatory for all controlled substances (Texas eliminated paper prescriptions)
• Licensure: Must hold Texas medical license or use IMLC (Texas is a compact state for physicians)

Bottom Line: Texas is the toughest state in our list for telehealth ADHD care. If you’re an NP, you can evaluate patients and manage therapy, but a physician must sign off on every stimulant prescription. For telehealth platforms, this means either recruiting Texas psychiatrists directly or arranging physician oversight for NP-led care. It’s doable, but it’s a constraint.

Florida: Explicit Permission with NP Caveats

The Rules:Florida law explicitly permits prescribing Schedule II controlled substances via telehealth for psychiatric disorders – and ADHD qualifies. This is written directly into statute (FS §456.47), making Florida one of the clearest states on this issue.

You cannot prescribe Schedule II via telehealth for other purposes (like pain management or weight loss), but mental health treatment is carved out.

NP Scope:Florida allows psychiatric nurse practitioners to prescribe stimulants, but with conditions:

1. Supervision Required: PMHNPs must practice under a protocol agreement with a supervising psychiatrist. Florida didn’t include psychiatric NPs in its 2020 independent practice law (that only covered primary care/family NPs).

2. No 7-Day Limit for Psych NPs: General Florida NPs are limited to 7-day supplies of Schedule II for acute conditions, but ‘psychiatric nurses’ (PMHNPs with ≥2 years post-grad psych experience under a psychiatrist) are exempt from that limit. They can prescribe full 30-day supplies of stimulants.

3. Minors: If treating children, the PMHNP must have a consulting pediatrician or psychiatrist involved for prescribing psychotropic controlled meds.

Out-of-State Providers:Florida offers an out-of-state telehealth registration that allows providers licensed elsewhere to treat Florida patients without obtaining a full Florida license. This registration covers psychiatric telemedicine and controlled substance prescribing (since ADHD is a mental health exception). However, you still need a DEA registration covering Florida and must register with Florida’s PDMP (E-FORCSE).

Key Requirements:

• E-FORCSE PDMP: Mandatory check before prescribing controlled substances for patients age 16+
• Licensure: Florida medical license or out-of-state telehealth registration
• Telehealth consent: Document patient consent per Florida telehealth rules

Bottom Line: Florida’s explicit statutory permission makes it a telehealth-friendly state for ADHD care, and the out-of-state registration option is a major advantage for multi-state platforms. Just ensure NPs have proper physician oversight in place.

New York: Recently Aligned with Federal Rules

The Rules:New York updated its regulations in May 2025 to explicitly allow prescribing controlled substances via telehealth when consistent with federal law. Prior to this, NY had mirrored the Ryan Haight Act’s in-person requirement, which technically created a state-level barrier even when DEA waived it federally.

The May 2025 guidance from NYSDOH clarifies: no in-person exam required as long as federal rules permit it. When DEA’s permanent rules kick in, New York’s regulations will require compliance with those as well.

NP Scope:New York is progressive for nurse practitioners. Under the NP Modernization Act (2015), experienced NPs (>3,600 hours of practice) can practice independently without a written collaborative agreement. They still need a defined collaborative relationship with a physician, but no direct supervision.

PMHNPs can prescribe Schedule II–V controlled substances with their own DEA registration and NYS Bureau of Narcotic Enforcement prescriber number. There are no state-specific quantity limits for NP prescribing of stimulants – they can prescribe up to the same limits as physicians.

Unique NY Feature:New York allows prescribers to issue up to a 90-day supply of stimulants for ADHD (instead of the usual 30-day limit for Schedule II) if the prescription notes ‘Code B’ indicating ADHD/minimal brain dysfunction. This applies to both physicians and NPs and can significantly reduce prescription hassle for stable telehealth patients.

Key Requirements:

• I-STOP PMP Registry: Mandatory check before prescribing any Schedule II, III, or IV controlled substance – highly enforced
• E-prescribing: Required for all controlled substances (NY mandated this in 2016)
• Licensure: Must hold New York medical license (NY isn’t in IMLC; no telehealth registration option)

Bottom Line: New York’s 2025 regulatory update removed any state-level ambiguity about telehealth prescribing. The combination of NP independence and the 90-day supply option makes NY attractive for telehealth ADHD practices, though you’ll need to invest in getting a NY license to practice there.

Pennsylvania: NP Oversight and 30-Day Limits

The Rules:Pennsylvania doesn’t prohibit telehealth prescribing of controlled substances at the state level – the medical and osteopathic boards have clarified that valid patient-provider relationships can be established via telemedicine, and prescribing is acceptable if the standard of care is met.

No state law adds barriers beyond federal requirements (Ryan Haight waivers apply).

NP Scope:Pennsylvania is a restricted practice state for nurse practitioners. CRNPs must have a collaborative agreement with a physician to practice and prescribe.

For controlled substances:

• 30-Day Limit: CRNPs can prescribe Schedule II controlled substances for up to 30 days
• Physician Approval: Any continuation beyond 30 days requires approval from the collaborating physician
• 90 Days for Schedule III/IV: NPs can prescribe up to 90-day supplies of Schedule III or IV (not relevant for most ADHD meds, which are Schedule II)

This means for ongoing ADHD treatment with stimulants, the supervising psychiatrist needs to review and approve continued prescribing monthly or authorize standing protocols for refills.

Key Requirements:

• PA PDMP: Required check before prescribing controlled substances at the start of a new course of treatment; best practice is to check for every stimulant prescription
• E-prescribing: Mandatory for controlled substances (Act 96 of 2018)
• Licensure: Pennsylvania medical license required (PA is in IMLC for physicians, which expedites out-of-state licensing)

Bottom Line: Pennsylvania’s NP oversight requirements mean telehealth platforms need either direct psychiatrist care or robust collaboration systems for NP-physician teams. The 30-day limit on NP stimulant prescriptions isn’t a dealbreaker, but it does require more physician involvement than in independent-practice states.

Illinois: Two-Tiered NP System

The Rules:Illinois permits telehealth broadly with no state-level barriers to prescribing controlled substances via telemedicine. The state’s Telehealth Act (updated 2021) ensures parity and allows provider-patient relationships to be established virtually.

NP Scope:Illinois operates a two-tiered system for APRNs:

Tier 1 – Collaborative Practice:NPs under a physician collaborative agreement can prescribe Schedule II controlled substances for up to 30 days, with physician approval required for any continuation. The collaborating physician must conduct monthly reviews of the NP’s Schedule II prescribing.

This is similar to Pennsylvania’s model but includes the monthly review requirement.

Tier 2 – Full Practice Authority:Illinois allows APRNs who complete 4,000 hours of collaborative practice plus 250 hours of continuing education to apply for Full Practice Authority (FPA). FPA APRNs can practice and prescribe independently.

Here’s the key distinction: FPA rules require a ‘consultation relationship’ with a physician for prescribing Schedule II narcotic drugs (opioids) or benzodiazepines. However, stimulants are Schedule II non-narcotic drugs, so the consultation requirement doesn’t apply to ADHD medications.

An FPA-certified PMHNP in Illinois can prescribe Adderall independently via telehealth without any physician oversight or approval requirements.

Key Requirements:

• Illinois Controlled Substance License: In addition to your DEA registration, you need a state-level CS license from IDFPR
• PMP Checks: Required for opioids and first-time benzos; recommended for all controlled substances including stimulants
• Licensure: Illinois medical license required (physicians can use IMLC for expedited licensing)

Unique Feature:Illinois allows prescribing psychologists with advanced training to prescribe certain psychotropic medications under physician collaboration. However, they’re excluded from prescribing Schedule II substances, so ADHD stimulants are off-limits for them.

Bottom Line: Illinois’s FPA pathway creates a clear advantage for experienced psychiatric NPs who can operate autonomously for ADHD care. The two-tiered system means you need to know which type of NP you’re working with, but the regulations themselves are clear and supportive of telehealth.

Comparison Table: Priority States at a Glance

Practical Compliance Checklist for Telehealth ADHD Prescribing

Whether you’re joining a platform like Klarity or running your own practice, here’s what you need to stay compliant in 2026:

Federal Requirements (All States)

• [ ] Active DEA registration covering the patient’s state
• [ ] Conduct evaluation via real-time audio-video (not phone-only, not just questionnaires)
• [ ] Document the evaluation thoroughly (diagnosis, symptom assessment, treatment rationale)
• [ ] Prescribe for a legitimate medical purpose (proper ADHD diagnosis per DSM criteria)
• [ ] Use electronic prescribing for controlled substances (EPCS-certified system)
• [ ] Stay current on DEA rule changes (telemedicine special registration likely required in 2027)

State-Specific Requirements

• [ ] Medical license in the patient’s state (not your state – where the patient is physically located)
• [ ] State-level controlled substance license if required (IL, NY Bureau of Narcotics number)
• [ ] PDMP check before prescribing Schedule II stimulants:
• California: CURES – initial + every 4 months
• Florida: E-FORCSE – every time for patients 16+
• New York: I-STOP – every time for Schedule II
• Pennsylvania: PA PDMP – initial + periodic
• Illinois: Recommended for all controlled substances
• Texas: Recommended (not mandated for stimulants)
• [ ] Verify your scope of practice in that state:
• If you’re an NP, know whether you need physician collaboration and any quantity limits (30-day in PA/IL collaborative practice, none in CA/NY/IL FPA)
• If you’re a physician, you’re generally clear in all states
• [ ] Document telehealth consent where required (FL explicitly requires it; others recommend it as best practice)
• [ ] For pediatric ADHD patients, ensure parent/guardian consent and involvement (some states like FL require consulting physician for minors)

Platform Benefits (Why Klarity Makes This Easier)

If you’re evaluating whether to go solo or join a platform:

DIY Reality:

• You’re responsible for multi-state licensing applications (expensive and time-consuming)
• You need your own EPCS software, telehealth technology, EHR, and PDMP integrations for every state
• You’re gambling $3,000–5,000/month on patient acquisition with zero guarantees
• You’ll spend hours navigating DEA rule changes and state medical board updates
• Cold leads from directories have 40–60% no-show rates

Klarity’s Model:

• Built-in telehealth infrastructure with state-specific compliance guardrails
• Pre-qualified ADHD patients matched to your specialty and availability
• Pay-per-appointment model: no upfront marketing spend, no monthly subscription fees – you only pay when a patient books
• Platform handles PDMP integrations and regulatory updates
• Both insurance and cash-pay patient flow
• You control your schedule and patient volume

Think of it as trading unpredictable marketing costs for predictable patient acquisition economics. For most providers – especially those starting out or scaling – that’s the smart play.

What’s Coming in 2027 and Beyond

DEA’s Permanent Rules

Expect final rules to publish in early 2027 with an implementation period. Key elements likely to include:

1. Telemedicine Special Registration required to prescribe controlled substances to new patients without in-person exams
2. Mandatory nationwide PDMP checks integrated into prescribing workflow
3. Platform registration requirements (DEA oversight of telehealth companies)
4. Patient identity verification standards for video consultations

State Trends to Watch

Expanding NP Independence:

• California’s transition to FPA completes in 2026
• Multiple states (including PA) have pending legislation to remove physician supervision requirements
• Expect more states to follow Illinois’s model of tiered independence based on experience

Telehealth Parity:

• Most states are moving toward permanent telehealth parity laws (requiring insurance coverage equivalent to in-person)
• Some states may add specific telehealth practice standards, but trend is toward access expansion, not restriction

PDMP Mandates:

• Expect more states to mandate PDMP checks for all controlled substances, not just opioids
• Interstate PDMP data sharing is expanding (currently 49 states + DC participate in some form of data exchange)

ADHD Treatment Landscape

The post-pandemic surge in ADHD diagnoses isn’t slowing down. Adult ADHD diagnoses increased 400%+ from 2020–2023, and telehealth was the primary driver. While there’s been regulatory scrutiny (DEA investigations of some telehealth startups for alleged over-prescribing), the overall policy direction is toward maintaining access with appropriate safeguards.

What this means for providers:

• Robust documentation is more important than ever (thorough diagnostic evaluations, not just symptom checklists)
• Conservative prescribing practices (appropriate dosing, monitoring for diversion) will help you avoid scrutiny
• Platforms that prioritize clinical quality over volume will be better positioned long-term

FAQ: What Providers Actually Want to Know

Can I prescribe Adderall to a patient in another state via telehealth?

Short answer: Yes, through the end of 2026, as long as:

1. You hold a medical license in that patient’s state
2. You have a DEA registration covering that state
3. You follow that state’s prescribing requirements (PDMP checks, e-prescribing, scope of practice rules)

After 2026: Likely yes with a telemedicine special registration, but wait for final DEA rules.

Do I need to see ADHD patients in person eventually?

Currently: No. Federal waivers allow entirely virtual care through December 31, 2026.

After 2027: Depends on DEA’s final rules. Options will likely include:

• Obtaining telemedicine special registration (no in-person required)
• Arranging at least one in-person visit to establish care
• Having the patient seen in-person by another provider in your practice

What happens if I accidentally prescribe to a patient in a state where I’m not licensed?

This is practicing medicine without a license – a serious legal issue. Most telehealth platforms (including Klarity) have geographic verification built in to prevent this. If you’re practicing independently, implement strict intake procedures to verify patient location at every visit (patients travel, use VPNs, etc.).

Can I use audio-only (phone) for ADHD visits?

For controlled substances: No. DEA’s current flexibilities require real-time audio-video communication for prescribing controlled substances. Audio-only was permitted for buprenorphine (opioid use disorder treatment) under specific circumstances, but hasn’t been extended to Schedule II stimulants.

For therapy/follow-up: Some states allow audio-only for psychotherapy, but it’s safest to use video for any visit where prescribing might occur.

What if a patient’s PDMP shows they’re getting stimulants from another provider?

This is exactly why PDMP checks are required. If you discover:

• Overlapping prescriptions: Contact the other provider and document why you’re continuing (often it’s a care transition or one provider is discontinuing)
• Doctor shopping red flags: Decline to prescribe and document your clinical reasoning
• Legitimate multiple providers: Sometimes patients see separate providers for ADHD vs. other conditions; verify coordination of care

Document every PDMP check and your clinical decision-making. This protects your license if regulators review your prescribing.

Are there any ADHD medications I can prescribe more easily via telehealth?

Schedule II stimulants (Adderall, Ritalin, Vyvanse, Concerta) all fall under the same federal restrictions.

Non-stimulant alternatives have fewer restrictions:

• Strattera (atomoxetine): Not scheduled – standard prescribing rules apply
• Intuniv/Kapvay (guanfacine/clonidine): Not scheduled
• Qelbree (viloxazine): Not scheduled

These can be prescribed via telehealth with a standard evaluation (no DEA rules), though you still need appropriate state licensure and a proper diagnosis. Many telehealth providers start with non-stimulants for new patients to establish care before moving to stimulants if needed.

Can I treat pediatric ADHD via telehealth?

Legally: Yes, in most states, with the same rules as adults (plus parent/guardian consent and often involvement in the visit).

Practically: Evaluating children via telehealth is more challenging:

• Parent/teacher rating scales are helpful but need triangulation
• Direct observation is limited compared to in-office
• Some states (like Florida) require psychiatric NPs to have physician consultation for prescribing to minors

Many providers prefer to see children in person at least once, even if not required, to get a more complete evaluation. For established patients (already diagnosed), telehealth follow-ups work well.

The Business Case: Why ADHD Telehealth Makes Sense in 2026

Market Demand

Patient Side:

• 10+ million U.S. adults with ADHD, only ~20% receiving treatment
• 6–12 month wait times for psychiatry appointments in many markets
• Patient preference for virtual care (convenience, less stigma)
• Both insured and cash-pay patients willing to pay for access

Provider Side:

• Average psychiatrist sees 30–40 patients/week at $200–300/visit = $240K–468K/year
• Telehealth eliminates office overhead (rent, support staff for scheduling/billing)
• Can see patients across multiple states (with proper licensing)
• Higher patient satisfaction = lower no-show rates

Economic Models

Traditional Practice:

• Office rent: $2,000–5,000/month
• Staff (front desk, billing): $3,000–6,000/month
• EHR, malpractice, marketing: $2,000–4,000/month
• Total overhead: $7,000–15,000/month before seeing first patient

Telehealth (DIY):

• EHR/telehealth platform: $200–500/month
• Marketing (if DIY): $3,000–5,000/month with 3–6 month ramp-up
• Directory fees (Psychology Today, Zocdoc): $500–1,000/month
• Malpractice: $500–1,000/month
• Total: $4,200–7,500/month + uncertain patient flow

Platform Model (Klarity):

• No monthly overhead
• Pay per booked appointment (varies by insurance vs. cash-pay)
• Immediate patient flow (no ramp-up period)
• Total: Pay only when you see patients

Break-even math:

• If you’re paying $50–100 per booked appointment to a platform vs. $5,000/month in marketing costs, you break even at 50–100 appointments/month
• Most providers on platforms see 20–40 patients/week (80–160/month)
• At that volume, platform economics beat DIY marketing by a wide margin

Risk Profile

DIY Risks:

• Marketing spend with no guaranteed return
• 3–6 months to see results from SEO
• Compliance burden (managing multi-state licenses, regulations, PDMP integrations)
• Technology stack maintenance
• Patient acquisition cost variability (Google Ads costs fluctuate)

Platform Benefits:

• Zero marketing risk (only pay for booked patients)
• Compliance infrastructure built-in
• Technology maintained by platform
• Predictable economics
• Focus on clinical care, not business operations

For most providers, especially those starting out or scaling, the platform model removes enough risk to make telehealth ADHD care viable.

Making the Move: Next Steps

If you’re ready to start or expand telehealth ADHD care:

1. Get Your Licensing Right

• Identify which states have the highest demand (CA, TX, FL, NY, PA, IL are priority markets)
• Apply for licenses in states where you want to practice (use IMLC if you’re a physician and both your home state and target state participate)
• For NPs: verify your scope in each state and identify whether you need physician collaboration

2. Set Up Compliance Infrastructure

• Obtain DEA registrations for each state
• Get state controlled substance licenses where required (IL, NY)
• Set up EPCS (Electronic Prescribing of Controlled Substances) capability
• Register with each state’s PDMP

3. Choose Your Practice Model

• Solo: Higher autonomy, higher risk, 3–6 month patient acquisition ramp
• Platform: Lower risk, immediate patient flow, built-in compliance support

4. Prepare for 2027 Rules

• Budget time/cost for DEA telemedicine special registration when available
• Develop backup plans (periodic in-person visits, or focus only on established patients if regulations tighten)
• Stay connected to professional associations for regulatory updates

5. Focus on Quality

• Develop thorough evaluation protocols (rating scales, clinical interview templates)
• Document conservatively (clear diagnostic criteria, treatment rationale)
• Monitor outcomes (symptom improvement, side effects, medication adherence)
• Build referral relationships for complex cases or co-morbidities

Ready to Join Klarity’s Provider Network?

Klarity handles the complexity of multi-state compliance, patient acquisition, and telehealth infrastructure so you can focus on clinical care. Our model gives you:

✅ Pre-qualified ADHD patients matched to your availability
✅ Built-in PDMP integrations and state-specific compliance tools
✅ Pay-per-appointment economics (no upfront marketing spend)
✅ Both insurance and cash-pay patient flow
✅ Full control over your schedule and patient volume

Whether you’re a psychiatrist looking to expand into telehealth or a PMHNP seeking a platform with proper state compliance, we’ve built our network to support your practice growth while navigating the regulatory landscape.

Apply to Join Klarity’s Provider Network and start seeing patients within weeks, not months.

Sources and Citations

The following sources were consulted to ensure accuracy of federal and state regulatory information presented in this guide:

1. DEA & HHS Press Release – Extension of Telemedicine Flexibilities Through 2026 (January 2, 2026)
   https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html
   Official government announcement of fourth extension through December 31, 2026

2. Healthcare Dive – DEA, HHS extend telehealth controlled substance prescribing flexibilities for fourth time (January 5, 2026)
   https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/
   Industry news article summarizing extension scope and implications

3. DEA Press Release – Three New Telemedicine Rules (January 16, 2025)
   [https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-

Source:

• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,II%20to%20Schedule%20V%20drugs
• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,to%20hash%20out%20permanent%20regulations
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Proposed%20DEA%20rules%20create%20a,for%20telemedicine%20prescribing
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=there%20any%20settings%20other%20than,may%20prescribe%20Schedule%20II%20controlled
• https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth#:~:text=as%20such%20terms%20are%20defined,the%20use%20of%20electronic%20prescribing
• https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html#:~:text=,
• https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300#:~:text=match%20at%20L5536%203,collaborating%20physician%20or%20podiatric%20physician
• https://rxagent.co/blog/np-prescribing-authority#:~:text=However%2C%20,3
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Prescribing%2C%20dispensing%2C%20or%20furnishing%20dangerous,the%20appropriate%20standard%20of%20care